AbbVie’s VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for the Treatment of Schizophrenia
VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022 . Following the positive recommendation from INESSS issued...